Evidence map›Paper›PMID 36361535›Full record

ArticleInternational journal of molecular sciences2022

Pioglitazone Modifies Kupffer Cell Function and Protects against

Hiromi Miyazaki, Manabu Kinoshita, Hiroyuki Nakashima, Shingo Nakamura, Daizoh Saitoh

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Determination of Burn Size in Mouse Models of Burn Injury: A Scoping Review of Studies Leveraging Scald and Contact Burns.Journal of burn care & research : official publication of the American Burn Association · 2025
    Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hiromi MiyazakiDivision of Biomedical Engineering, National Defense Medical College Research Institute, Saitama 359-8513, Japan.ORCID 0000-0001-7719-4913
Manabu KinoshitaDepartment of Immunology and Microbiology, National Defense Medical College, Saitama 359-8513, Japan.
Hiroyuki NakashimaDepartment of Immunology and Microbiology, National Defense Medical College, Saitama 359-8513, Japan.ORCID 0000-0001-6066-3031
Shingo NakamuraDivision of Biomedical Engineering, National Defense Medical College Research Institute, Saitama 359-8513, Japan.ORCID 0000-0001-6084-0958
Daizoh SaitohDivision of Traumatology, National Defense Medical College Research Institute, Saitama 359-8513, Japan.
National Defense Medical College · JP

Funding

Japan Society for the Promotion of Science JP20H03785
6 · The paper itself

Abstract

Infectious complications and subsequent sepsis in severely burned patients lead to high morbidity and mortality in response to uncontrolled innate immune responses mediated by macrophages. Peroxisome proliferator-activated receptor gamma (PPARγ) has anti-inflammatory activity and acts as a master regulator of macrophage polarization. In this study, we investigated whether the administration of a PPARγ agonist could modulate the Kupffer cell phenotype and thereby ameliorate the dysregulated innate response during post-burn bacterial infection. C57BL/6 mice were subjected to severe burns and randomized to receive either the PPARγ agonist, pioglitazone, or the vehicle control five days after injury, followed by the subsequent analysis of hepatic macrophages. Survival from the bacterial infection was monitored for seven days. Pioglitazone protected burned mice against bacterial infection. A single treatment with pioglitazone significantly enhanced phagocytosis, phagosome acidification, bacterial clearance, and reduction in inflammatory mediators in Kupffer cells. In conclusion, PPARγ activation by pioglitazone prevents clinical deterioration due to post-burn bacterial infection and improves survival. Our findings suggest that pioglitazone may be an effective therapeutic candidate for post-burn infectious complications.

Indexed as

BacteremiaEscherichia coli InfectionsThiazolidinedionesAnimalsEscherichia coliHypoglycemic AgentsKupffer CellsMiceMice, Inbred C57BLPioglitazonePPAR gammaHypoglycemic AgentsPioglitazonePPAR gammaThiazolidinedionesbacterial clearanceburnsinfectionKupffer cellsphagocytosisPPARγ

Identifiers

PMID36361535
PMCPMC9657905
OpenAlexW4307265860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.